Brenipatide (LY3537031) Phase 2 IBS-C Study, 35 Weeks, NCT07545772
Summary
A Phase 2 clinical trial (NCT07545772) for Brenipatide (LY3537031) in participants with Irritable Bowel Syndrome-Constipation (IBS-C) has been registered on ClinicalTrials.gov. The approximately 35-week study will evaluate safety, tolerability, and efficacy of subcutaneous Brenipatide compared to placebo. The trial is listed with an anticipated start date of April 22, 2026, and represents an active development milestone for this investigational gastrointestinal therapy.
“The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 2 clinical trial for Brenipatide (LY3537031), an investigational therapy for Irritable Bowel Syndrome-Constipation (IBS-C), has been registered on ClinicalTrials.gov under identifier NCT07545772. The approximately 35-week study will randomize participants to receive subcutaneous Brenipatide or placebo, with co-primary endpoints related to tolerability, safety, and efficacy. For pharmaceutical companies and clinical research organizations monitoring the IBS-C therapeutic landscape, this trial registration signals continued investment in novel gut-brain axis or secretory pathway therapies for functional gastrointestinal disorders.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Phase 2 NCT07545772 Kind: PHASE2 Apr 22, 2026
Abstract
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.
The study will last approximately 35 weeks.
Conditions: Irritable Bowel Syndrome, Constipation
Interventions: LY3537031, Placebo
Mentioned entities
Parties
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.